

GOVERNMENT OF INDIA

MINISTRY OF AYUSH

LOK SABHA

UNSTARRED QUESTION NO.2321

TO BE ANSWERED ON 13th FEBRUARY 2026

Projects under ABIHR Component

†2321. Shri Ramesh Awasthi:

Shri Yaduveer Wadiyar:

Shri Manoj Tiwari:

Shri Ravindra Shukla *Alias* Ravi Kishan:

Smt. Sanjna Jatav:

Shri Sukanta Kumar Panigrahi:

Shri Khagen Murmu:

Dr. Nishikant Dubey:

Shri Jugal Kishore:

Shri Alok Sharma:

Shri Nalin Soren:

Dr. Vinod Kumar Bind:

Shri Pratap Chandra Sarangi:

Will the Minister of AYUSH be pleased to state:

- (a) whether under the Ayurveda Biology Integrated Health Research (ABIHR) component, financial grants have been sanctioned and released for the 11 projects in the country including Jammu and Kashmir, Madhya Pradesh and Dumka district of Jharkhand;
- (b) if so, the details thereof, State/UT-wise;
- (c) the total number of specialized Good Laboratory Practice (GLP) compliant laboratories that have been outsourced by the Central Council for Research in Ayurvedic Sciences (CCRAS) for the preparation of quality to and safety dossiers for the five prioritized botanicals and their compliance with international regulatory standards;
- (d) the details of the botanicals out of these five herbal medicines that have successfully completed their quality and safety dossiers by December 2025;
- (e) whether the regulatory dossiers prepared under the ABIHR "pro-active approval" initiative comply with international regulatory standards for export; and

(f) if so, the details thereof along with the total expenditure incurred on this initiative up to December 2025?

ANSWER

THE MINISTER OF STATE (IC) OF THE MINISTRY OF AYUSH
(SHRI PRATAPRAO JADHAV)

(a) & (b) The Central Sector Scheme, namely Ayurgyan scheme is being implemented by Ministry of Ayush throughout the country and not specific to any State/UTs and regions. Under the Ayurveda Biology Integrated Health Research (ABIHR) component of the Ayurgyan Scheme, financial grants have been sanctioned and released to the eligible organizations/institutions across the country for conducting 11 research projects as per the provisions contained in the scheme guidelines. The details of the same are attached at Annexure.

(c) For the preparation of quality and safety dossiers for the five prioritized botanicals and their compliance with international regulatory standards, five (05) Good Laboratory Practice (GLP) compliant laboratories have been identified and outsourced by the Central Council for Research in Ayurvedic Sciences (CCRAS).

(d) Under the ABIHR, the financial assistance to the supported organisation were provided from 2024-25 for a duration of 02 years. Therefore, as of December 2025, none of the projects have been completed.

(e) & (f) The drug development dossiers on the following 05 single botanicals are being developed in compliance with internationally accepted regulatory standards viz. United States Food and Drug Administration (US-FDA):

- i) Ashwagandha (*Withania somnifera*)
- ii) Brahmi (*Bacopa monieri*)
- iii) Shallaki (*Boswellia serrata*)
- iv) Shunthi (*Zinziber officinale*)
- v) Methika (*Trigonella foenum-graecum*)

These drug development dossiers include comprehensive scientific data on quality, safety and regulatory documentation generating through selected GLP-compliant laboratories, with the objective of facilitating international regulatory acceptance and promoting export of Ayurveda botanicals. Total expenditure incurred under this initiative up to December 2025 is Rs. 33.498 Crore.

Annexure**Details of ongoing research projects (11 nos.) under ABIHR component Ayurgyan Scheme, Ministry of Ayush****(In Rupees)**

State	Name of Organization	Project Title	Fund approved	Fund released
Andhra Pradesh	Laila Neutraceuticals Vijaywada	Development of drug master file and technical dossiers on selected single botanicals used in Ayurveda	9,98,69,000/-	5,60,00,000/-
	Laila Neutraceuticals Vijaywada	Development of Technical dossier of Trigonella Foenum graecum - Stage I (preclinical studies- oral toxicity, genotoxicity, efficacy, Pharmacokinetic studies and safety pharmacology in rodents)	9,99,08,622/-	4,99,54,311/-
Gujarat	Jai Research Foundation, Valsad	Development of Technical dossier of Zingiber Officinale- Stage I (preclinical studies- oral toxicity, genotoxicity, efficacy, Pharmacokinetic studies and safety pharmacology in rodents)	9,97,70,000/-	4,98,85,000/-
Karnataka	Adigyl Lifesciences Pvt. Ltd	Development of Technical dossier of Bacopa monnieri- Stage I (preclinical studies- oral toxicity, genotoxicity, efficacy, Pharmacokinetic studies and safety pharmacology in rodents)	9,98,63,500/-	4,99,31,750/-
	Indian Institute of Science, Bangalore	Investigation of potential leads from Ayurveda therapeutics for management of Antimicrobial Resistance (AMR)	9,94,00,000/-	4,72,00,000/-
Madhya Pradesh	Regional Ayurveda Research Institute, Aamkho, Gwalior,	Preclinical Toxicological Evaluation and Safety Pharmacology of Selected Ayurvedic Formulations Triphala churna, Lashunadi vati, and Brihat Vata Chintamani Rasa	5,88,02,520/-	1,56,70,884/-
Maharashtra	Intox Pvt. Ltd. Pune	Development of Technical dossier of Boswellia serrata- Stage I (preclinical studies- oral toxicity, genotoxicity, efficacy, Pharmacokinetic studies and safety pharmacology in rodents)	9,96,99,600/-	4,98,49,800/-

	Regional Ayurveda Research Institute, Kothrud, Pune	Preclinical Toxicological Evaluation and Safety Pharmacology of Selected Ayurvedic Formulations - Laksha Guggulu, Dadimadi Ghrita and Ekangaveera Rasa	4,01,97,624/-	2,36,63,920/-
Uttar Pradesh	Dabur Research foundation, Ghaziabad	Development of Technical dossier of Withania somnifera - Stage I (preclinical studies- oral toxicity, genotoxicity, efficacy, Pharmacokinetic studies and safety pharmacology in rodents)	9,92,01,960/-	7,93,61,568/-
West Bengal	Central Ayurveda Research Institute, Kolkata	Preclinical Toxicological Evaluation and Safety Pharmacology of Rajah Pravartini Vati, Phala Ghrita and Drakshavaleha	5,95,21,140/-	3,39,10,380/-
	School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University	Toxicological Evaluation, Safety Assessment, and Metabolomic Profiling of Selected Ayurvedic drugs and Formulations	9,66,00,000/-	5,48,33,332/-